[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
C4x Discovery Holdings Plc LSE:C4XD London Ordinary Share GB00BQQ2RV18 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 28.00 27.50 28.50 28.00 28.00 28.00 34,729 08:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -9.6 -8.1 - 63

C4x Discovery Share Discussion Threads

Showing 2276 to 2299 of 2625 messages
Chat Pages: Latest  93  92  91  90  89  88  87  86  85  84  83  82  Older
DateSubjectAuthorDiscuss
03/11/2020
17:09
Nice candle (albeit low volume) We are getting closer to a potential Golden Cross
the stigologist
03/11/2020
13:54
htTps://twitter.com/MarketofStocks/status/1323620535654322176?s=20
the stigologist
03/11/2020
11:35
For the first time ever I agree lol
alloa2003
03/11/2020
11:08
Breaking out ish
the stigologist
02/11/2020
07:32
I won't accept anything less than 500% for C4XD, PYC, or DDDD.
hodhasharon
02/11/2020
07:29
WOW WALL OF MONEY Sanofi paying 272% premium for Kiadis today htTps://twitter.com/KiadisPharma/status/1323146583085621248?s=20
the stigologist
31/10/2020
13:04
Missed this in first reading In August 2020, the Company announced that significant progress has been made on C4XD’s early oral inhibitor programme targeting α4β7 integrin for the treatment of IBD. Effective antibody therapy against this target is already approved, removing the clinical target risk, but effective oral therapy remains highly sought after. C4XD has identified a second series of novel, potent and selective inhibitors providing a further competitive edge for this programme. This reaffirms the capability of C4XD’s Conformetrix technology to discover novel chemical scaffolds for high-value challenging drug targets. Both series have recently demonstrated oral bioavailability in PK studies with the current focus on improving PK properties to demonstrate functional inhibition of α4β7 integrin in vivo following oral dosing. The Company is currently generating improved molecules to move to in vivo studies and despite being early stage, the Company is in discussion with several potential partners, which are under CDA.
the stigologist
30/10/2020
16:47
Good close to the week
the stigologist
30/10/2020
12:30
There must be a buyer in the market as you would have expected the constant drip feed of sellers, and no announced buyers, over the last few days to drag the price even further down. All very interesting
alloa2003
29/10/2020
16:50
I see Stig has found his copy and paste buttons again
alloa2003
29/10/2020
11:09
EARLY STAGE ASSET DEVELOPMENT (ESAD) ▪ INDV-2000 (Selective Orexin 1 [OX1] receptor antagonist): - The Single Ascending Dose (SAD) study is ongoing. The first subject was dosed on July 28, 2020. - Nonclinical pivotal toxicokinetics and embryofetal studies have been completed.
the stigologist
28/10/2020
23:37
Commenting on the transaction, lead partner at Pinsent Masons Charles Waddell said: "We have enjoyed working with 4D for a number of years, they are at the cutting edge of live biotherapeutic products and this transaction is an important step in their future development and access to key to international markets. Given the number of European biotechs that covet a move to NASDAQ, and notwithstanding the complex financing structures of SPACs, this deal highlights that there is an alternative route to the US markets. It is therefore unlikely to be the last biotech we see looking at SPACs to access the deep pool of sophisticated investors in the US.
the stigologist
28/10/2020
22:44
>alloa I agree. The only question is the length of time their balance sheet can fund. The Placing document says "The net proceeds of the Placing are expected to provide the Company with at least twelve months working capital" which I take NOT to mean two years. Perversely that's a good thing IMO
t0pgrader
28/10/2020
12:54
I agree but, as mentioned at the last fund raising, the company needs to be fully funded while discussing deals with partners. If I was a large pharma in discussions and I sniffed any sign of financial weakness, I would try to delay and tie the company up in knots. The weaker they are financially the more desperate they would be to sign. This money, with earlier funds and the INDV milestone when it happens, must surely cover funding for in excess of 2 years? Even whats left of the 2 x placing funds must still amount to at least 18 months financial headroom?
alloa2003
28/10/2020
12:46
Not sure there will be much very material by way of significant news until they announce the deal(s). CD telling us he is close/ in negotiations etc is (a) what we expect and (b) not a guarantee of a deal. It also places the company in a weaker negotiating position and is therefore always best avoided as a tactic. Unless something leaks I would expect the shareprice to remain calm for the foreseeable. The only exception might be a surprising addition to the shareholder register from the placing.
t0pgrader
28/10/2020
12:36
Yip totally agree t0pgrader Once we reach the tipping point where the company is self funding and royalty income grows year on year, that is when we will see the real long term value the company can offer. Until that point the price will likely be volatile and very very news driven.
alloa2003
28/10/2020
12:34
Quite agree alloa. The way I see it is they expect to announce the next licensing deal before the end of the current runway otherwise why would institutions invest such a significant sum relative to market cap now? "The net proceeds of the Placing are expected to provide the Company with at least twelve months working capital." The countdown is on......
t0pgrader
28/10/2020
11:46
I agree this company has the potential to be valued in the hundreds of millions of pounds but it will take more than a "simple sentiment switch". Once they deliver on the next INDV payment that will improve sentiment then we need to see regular deals and regular income. The key to a higher share price here is milestone payments going forward and royalties on all deals. This will increase the cumulative cash flow which will make the company self-funding, delivering more and more treatments going forward.
alloa2003
28/10/2020
09:29
C4XD Shares in Issue : 226m Share Price : 20p Mkt Cap : £45m Cash : c.£20m EV : £25m Potential milestones on INDV2000 : $294m 11 Drug Discovery programmes 2 late stage programmes which they are looking to licence for same ball park figures as INDV deal You could easily see this Company being valued in the Hundreds of Millions with a simple sentiment switch
the stigologist
28/10/2020
09:25
That's true
the stigologist
28/10/2020
09:16
The way I see things with the glass half full is, if SAR can currently have a MCAP of around £70 million then anything is possible
pugg1ey
27/10/2020
21:47
INDV openly said they'd be concentrating strategy on INDV2000 They said that AFTER several 'milestone worthy' events since the first one C4XD are under no obligation to tell shareholders anything if it goes against the interests of shareholders by breaking commercial confidentiality The only people to lose are impatient/thick traders. Looking forward to INDV results this week. First since putting line under DoJ stuff. Now maybe they will be ore forthcoming on INDV2000 We haven't heard any negative leaks on safety from Phase I INDV said they would concentrate on it well into dosing so I suspect there have not been any major issues It will be onwards and upwards into Phase II and that definitely should lead to a milestone payment
the stigologist
27/10/2020
19:08
Agree .... i for one, would not have sold knowing this information,If this becomes the case, I'll be ringing Mr Dix and informing him of the price sensitive information being withheld to benefit institutional investors.And that's a big NO !!
amaretto1
27/10/2020
17:47
I would find it strange if soon they announced the second INDV instalment or a short term money earner because questions would be asked about the fund raising. All very interesting.
alloa2003
Chat Pages: Latest  93  92  91  90  89  88  87  86  85  84  83  82  Older
ADVFN Advertorial
Your Recent History
LSE
C4XD
C4x Discov..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211025 02:15:48